8-K Announcements
6Material company update
Jan 23, 2026·SEC
Material company update
Jan 21, 2026·SEC
Material company update
Dec 23, 2025·SEC
Astria Therapeutics, Inc.(ATXS)Earnings, Financials & Key Ratios
ATXS•NASDAQ
$12.58
$718M mkt cap·Price updated Apr 24, 2026
AboutAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$112M-13.6%
- Net Income-$94M-29.3%
- EPS (Diluted)-1.68+30.6%
- ROE-33.52%-6.8%
- ROIC-50.3%-8.9%
- Debt/Equity0.02+1139.2%
ATXS Key Insights
Astria Therapeutics, Inc. (ATXS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 86.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ATXS Price & Volume
Astria Therapeutics, Inc. (ATXS) stock price & volume — 10-year historical chart
Loading chart...
ATXS Growth Metrics
Astria Therapeutics, Inc. (ATXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.38%
Return on Capital
10 Years-92.64%
5 Years-88.23%
3 Years-35.42%
Last Year-39.4%
ATXS Recent Earnings
Astria Therapeutics, Inc. (ATXS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 0/12 qtrs (0%)
Q4 2025Latest
Nov 12, 2025EPS
$0.55
Est $0.41
-34.1%
Revenue
$706,000
Est $11M
-93.4%
Q3 2025
Aug 12, 2025EPS
$0.57
Est $0.61
+6.6%
Revenue
—
Est $11M
Q2 2025
May 13, 2025EPS
$0.58
Est $0.48
-20.8%
Revenue
—
Q2 2025
Mar 11, 2025EPS
$0.44
Est $0.45
+2.2%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.55vs $0.41-34.1% | $706,000vs $11M-93.4% |
| Q3 2025 | Aug 12, 2025 | $0.57vs $0.61+6.6% | —vs $11M |
| Q2 2025 | May 13, 2025 | $0.58vs $0.48-20.8% | — |
| Q2 2025 | Mar 11, 2025 | $0.44vs $0.45+2.2% | — |
Based on last 12 quarters of dataView full earnings history →
ATXS Peer Comparison
Astria Therapeutics, Inc. (ATXS) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KALV | 1.37B | 26.72 | -7.24 | -13.91% | -282.01% | 0.07 | ||
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 CGEM | 903.06M | 14.99 | -4.03 | -46.19% | 0.01 | |||
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare ATXS vs Peers
Astria Therapeutics, Inc. (ATXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATXS Income Statement
Astria Therapeutics, Inc. (ATXS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 500K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 706K |
| Revenue Growth % | - | - | -100% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 395K | 0 | 119K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -395K▲ 0% | 500K▲ 226.6% | -119K▼ 123.8% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 706K▲ 0% |
| Gross Margin % | - | 100% | - | - | - | - | - | - | - | 100% |
| Gross Profit Growth % | -95.54% | 226.58% | -123.8% | 100% | - | - | - | - | - | - |
| Operating Expenses | 35.56M | 27.59M | 26.37M | 27.09M | 37.44M | 194.98M | 53.5M | 83.03M | 111.56M | 137.22M |
| OpEx % of Revenue | - | 5518.8% | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 10.11M | 8.91M | 9.33M | 9.07M | 11.85M | 14.81M | 19.73M | 25.7M | 35.25M | 39.41M |
| SG&A % of Revenue | - | 1782.4% | - | - | - | - | - | - | - | - |
| Research & Development | 25.45M | 18.68M | 17.04M | 18.32M | 25.59M | 15.55M | 34.26M | 57.33M | 77.11M | 98.04M |
| R&D % of Revenue | - | 3736.4% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 93K | 32K | 176K | -303K | 0 | 164.62M | -487K | 0 | -801K | -231K |
| Operating Income | -35.56M▲ 0% | -27.09M▲ 23.8% | -26.37M▲ 2.7% | -27.09M▼ 2.7% | -37.44M▼ 38.2% | -194.98M▼ 420.8% | -53.5M▲ 72.6% | -83.03M▼ 55.2% | -111.56M▼ 34.4% | -136.51M▲ 0% |
| Operating Margin % | - | -5418.8% | - | - | - | - | - | - | - | -19335.69% |
| Operating Income Growth % | -12.32% | 23.8% | 2.67% | -2.72% | -38.2% | -420.84% | 72.56% | -55.19% | -34.36% | - |
| EBITDA | -35.16M | -26.79M | -26.25M | -27.06M | -37.41M | -30.36M | -53.5M | -98.23M | -111.56M | -134.05M |
| EBITDA Margin % | - | -5358% | - | - | - | - | - | - | - | -18987.11% |
| EBITDA Growth % | -11.78% | 23.81% | 2.01% | -3.09% | -38.23% | 18.85% | -76.23% | -83.6% | -13.57% | -2.08% |
| D&A (Non-Cash Add-back) | 395K | 304K | 119K | 26K | 26K | 0 | 0 | -15.2M | 0 | 0 |
| EBIT | -35.22M | -26.9M | -25.77M | -27.09M | -37.44M | -30.36M | -53.5M | -67.83M | -111.56M | -134.05M |
| Net Interest Income | -595K | -302K | 325K | 845K | 236K | 122K | 1.72M | 10.2M | 17.36M | 12.69M |
| Interest Income | 242K | 160K | 425K | 845K | 236K | 122K | 1.72M | 10.2M | 17.36M | 12.69M |
| Interest Expense | 837K | 462K | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -502K | -270K | 501K | 795K | 135K | 64K | 1.67M | 10.14M | 17.3M | 12.48M |
| Pretax Income | -36.06M▲ 0% | -27.36M▲ 24.1% | -25.87M▲ 5.5% | -26.29M▼ 1.6% | -37.3M▼ 41.9% | -194.91M▼ 422.6% | -51.83M▲ 73.4% | -72.89M▼ 40.6% | -94.26M▼ 29.3% | -124.03M▲ 0% |
| Pretax Margin % | - | -5472.8% | - | - | - | - | - | - | - | -17567.99% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -36.06M▲ 0% | -27.36M▲ 24.1% | -25.87M▲ 5.5% | -26.29M▼ 1.6% | -37.3M▼ 41.9% | -194.91M▼ 422.6% | -51.83M▲ 73.4% | -72.89M▼ 40.6% | -94.26M▼ 29.3% | -124.03M▲ 0% |
| Net Margin % | - | -5472.8% | - | - | - | - | - | - | - | -17567.99% |
| Net Income Growth % | -10.51% | 24.12% | 5.46% | -1.64% | -41.86% | -422.55% | 73.41% | -40.62% | -29.32% | -23.98% |
| Net Income (Continuing) | -36.06M | -27.36M | -25.87M | -26.29M | -37.3M | -194.91M | -51.83M | -72.89M | -94.26M | -124.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -133.31▲ 0% | -75.73▲ 43.2% | -30.71▲ 59.4% | -14.06▲ 54.2% | -12.20▲ 13.2% | -24.58▼ 101.5% | -3.55▲ 85.6% | -2.42▲ 31.8% | -1.68▲ 30.6% | -2.14▲ 0% |
| EPS Growth % | 45.24% | 43.19% | 59.45% | 54.22% | 13.23% | -101.48% | 85.56% | 31.83% | 30.58% | -2.38% |
| EPS (Basic) | -133.31 | -75.73 | -30.71 | -14.06 | -12.20 | -24.58 | -3.55 | -2.42 | -1.68 | - |
| Diluted Shares Outstanding | 270.5K | 361.36K | 842.47K | 1.87M | 3.06M | 8.93M | 14.62M | 30.12M | 56.16M | 58.01M |
| Basic Shares Outstanding | 270.5K | 361.36K | 842.47K | 1.87M | 3.06M | 8.93M | 14.62M | 30.12M | 56.16M | 58.01M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ATXS Balance Sheet
Astria Therapeutics, Inc. (ATXS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 39.53M | 17.46M | 38.91M | 38.96M | 46.33M | 127.08M | 227.69M | 250.94M | 334.64M | 253.55M |
| Cash & Short-Term Investments | 38.53M | 16.37M | 37.57M | 36.24M | 44.93M | 125.51M | 226.44M | 246.53M | 328.13M | 227.72M |
| Cash Only | 23.6M | 16.37M | 15.29M | 9.9M | 24.93M | 86.51M | 20.52M | 175.53M | 59.82M | 96.28M |
| Short-Term Investments | 14.93M | 0 | 22.28M | 26.34M | 20M | 39M | 205.91M | 71M | 268.31M | 131.44M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.24M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 2.23K |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1M | 1.09M | 0 | 0 | 0 | 0 | 1.25M | 4.41M | 6.51M | 8.58M |
| Total Non-Current Assets | 681K | 434K | 254K | 2.82M | 1.13M | 439K | 2.94M | 3.72M | 7.72M | 18.32M |
| Property, Plant & Equipment | 568K | 321K | 56K | 2.35M | 966K | 394K | 948K | 363K | 5.11M | 4.25M |
| Fixed Asset Turnover | - | 1.56x | - | - | - | - | - | - | - | 0.15x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 113K | 113K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 198K | 473K | 165K | 45K | 2M | 3.36M | 2.61M | 28.05M |
| Total Assets | 40.21M▲ 0% | 17.9M▼ 55.5% | 39.17M▲ 118.9% | 41.78M▲ 6.7% | 47.46M▲ 13.6% | 127.51M▲ 168.7% | 230.63M▲ 80.9% | 254.67M▲ 10.4% | 342.36M▲ 34.4% | 271.87M▲ 0% |
| Asset Turnover | - | 0.03x | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -37.39% | -55.49% | 118.86% | 6.67% | 13.59% | 168.7% | 80.87% | 10.42% | 34.44% | -31.84% |
| Total Current Liabilities | 8.32M | 6.02M | 4.17M | 5.03M | 6.39M | 5.2M | 9.06M | 11.55M | 19.13M | 23.52M |
| Accounts Payable | 1.41M | 773K | 1.41M | 1.2M | 1.54M | 1.56M | 788K | 1.51M | 4.32M | 1.14M |
| Days Payables Outstanding | 1.3K | - | 4.32K | - | - | - | - | - | - | - |
| Short-Term Debt | 3.24M | 2.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 2.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.5M |
| Other Current Liabilities | 0 | 332K | 1.52M | 1.36M | 2.12M | 1.96M | 3.37M | 4.05M | 0 | 4.85M |
| Current Ratio | 4.75x | 2.90x | 9.33x | 7.74x | 7.25x | 24.42x | 25.13x | 21.73x | 17.49x | 17.49x |
| Quick Ratio | 4.75x | 2.90x | 9.33x | 7.74x | 7.25x | 24.42x | 25.13x | 21.73x | 17.49x | 17.49x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 2.23K |
| Total Non-Current Liabilities | 2.8M | 89K | 56K | 1.03M | 397K | 0 | 357K | 0 | 3.97M | 15.1M |
| Long-Term Debt | 2.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 1.03M | 397K | 0 | 357K | 0 | 3.97M | 14.06M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 319K | 89K | 56K | 0 | 0 | 0 | 0 | 0 | 0 | 1K |
| Total Liabilities | 11.12M | 6.11M | 4.23M | 6.06M | 6.79M | 5.2M | 9.42M | 11.55M | 23.1M | 38.61M |
| Total Debt | 5.72M | 2.48M | 0 | 2.25M | 1.05M | 365K | 939K | 329K | 5.35M | 4.46M |
| Net Debt | -17.87M | -13.89M | -15.29M | -7.65M | -23.88M | -86.14M | -19.59M | -175.2M | -54.47M | -91.82M |
| Debt / Equity | 0.20x | 0.21x | - | 0.06x | 0.03x | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.68x |
| Interest Coverage | -42.48x | -58.65x | -263.71x | - | - | - | - | - | - | - |
| Total Equity | 29.09M▲ 0% | 11.79M▼ 59.5% | 34.94M▲ 196.3% | 35.72M▲ 2.2% | 40.67M▲ 13.9% | 122.31M▲ 200.7% | 221.22M▲ 80.9% | 243.12M▲ 9.9% | 319.26M▲ 31.3% | 233.25M▲ 0% |
| Equity Growth % | -42.4% | -59.46% | 196.32% | 2.23% | 13.86% | 200.75% | 80.86% | 9.9% | 31.32% | -46.68% |
| Book Value per Share | 107.53 | 32.63 | 41.48 | 19.14 | 13.30 | 13.70 | 15.13 | 8.07 | 5.68 | 4.02 |
| Total Shareholders' Equity | 29.09M | 11.79M | 34.94M | 35.72M | 40.67M | 122.31M | 221.22M | 243.12M | 319.26M | 233.25M |
| Common Stock | 19K | 24K | 7K | 12K | 4K | 13K | 28K | 41K | 57K | 57K |
| Retained Earnings | -144.07M | -171.43M | -197.3M | -223.6M | -260.9M | -455.81M | -507.64M | -580.53M | -674.79M | -773.2M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4K | 0 | -4K | 0 | 0 | 0 | -79K | 0 | 163K | 56K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATXS Cash Flow Statement
Astria Therapeutics, Inc. (ATXS) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -32.86M | -26.84M | -23.46M | -26.57M | -32.48M | -30.15M | -43.53M | -68.44M | -81.21M | -81.21M |
| Operating CF Margin % | - | -5367.2% | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -10.29% | 18.33% | 12.56% | -13.23% | -22.27% | 7.18% | -44.38% | -57.23% | -18.65% | -165.81% |
| Net Income | -36.06M | -27.36M | -25.87M | -26.29M | -37.3M | -194.91M | -51.83M | -72.89M | -94.26M | -124.03M |
| Depreciation & Amortization | 395K | 304K | 119K | 26K | 0 | 0 | 0 | 0 | 0 | -1.89M |
| Stock-Based Compensation | 2.16M | 2.01M | 1.77M | 1.51M | 1.39M | 3.36M | 4.55M | 6.31M | 13.04M | 11.59M |
| Deferred Taxes | 96K | -4K | -303K | 23K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 277K | 155K | 56K | 33K | 58K | 164.7M | 1.1M | 545K | -4.54M | 3.49M |
| Working Capital Changes | 274K | -1.93M | 762K | -1.87M | 3.37M | -3.31M | 2.65M | -2.41M | 4.54M | -8.89M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 77K | -632K | 662K | -211K | 347K | -1.97M | -766K | 725K | 2.81M | -142K |
| Cash from Investing | -15.49M | 14.88M | -21.91M | -4.08M | 6.3M | -12.55M | -167.13M | 135.05M | -191.86M | 135.11M |
| Capital Expenditures | -459K | -57K | 18K | -12K | -33K | -21K | -91K | -25K | -325K | -590K |
| CapEx % of Revenue | - | 11.4% | - | - | - | - | - | - | - | - |
| Acquisitions | 52K | 45.54M | -18K | 4.07K | -6.33K | 6.47M | 167.04K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 52K | 30K | 369K | -4.07K | 6.33K | 0 | -167.04K | 0 | 0 | 0 |
| Cash from Financing | 9.16M | 4.73M | 44.3M | 25.62M | 40.86M | 104.28M | 144.72M | 88.4M | 157.2M | 3K |
| Debt Issued (Net) | -3.33M | -3.33M | -2.85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 3K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 503K | 23K | 4K | 54K | 31K | 23K | 84K | 420K | 4.79M | 0 |
| Net Change in Cash | -39.18M▲ 0% | -7.23M▲ 81.6% | -1.07M▲ 85.1% | -5.03M▼ 368.0% | 14.68M▲ 391.7% | 61.58M▲ 319.6% | -65.94M▼ 207.1% | 155M▲ 335.1% | -115.87M▼ 174.8% | 15.38M▲ 0% |
| Free Cash Flow | -33.32M▲ 0% | -26.89M▲ 19.3% | -23.45M▲ 12.8% | -26.58M▼ 13.4% | -32.52M▼ 22.3% | -30.17M▲ 7.2% | -43.62M▼ 44.6% | -68.47M▼ 57.0% | -81.54M▼ 19.1% | -120.32M▲ 0% |
| FCF Margin % | - | -5378.6% | - | - | - | - | - | - | - | -17042.92% |
| FCF Growth % | -10.27% | 19.28% | 12.81% | -13.37% | -22.34% | 7.21% | -44.58% | -56.95% | -19.08% | -27.42% |
| FCF per Share | -123.17 | -74.42 | -27.83 | -14.24 | -10.63 | -3.38 | -2.98 | -2.27 | -1.45 | -1.45 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.98x | 0.91x | 1.01x | 0.87x | 0.15x | 0.84x | 0.94x | 0.86x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATXS Key Ratios
Astria Therapeutics, Inc. (ATXS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -90.63% | -133.88% | -110.71% | -74.42% | -97.66% | -239.19% | -30.18% | -31.4% | -33.52% | -53.17% |
| Return on Invested Capital (ROIC) | -677.55% | -445.92% | -225.39% | -85.14% | -125.18% | -552.31% | -33.75% | -46.21% | -50.3% | -50.3% |
| Gross Margin | - | 100% | - | - | - | - | - | - | - | 100% |
| Net Margin | - | -5472.8% | - | - | - | - | - | - | - | -17567.99% |
| Debt / Equity | 0.20x | 0.21x | - | 0.06x | 0.03x | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x |
| Interest Coverage | -42.48x | -58.65x | -263.71x | - | - | - | - | - | - | - |
| FCF Conversion | 0.91x | 0.98x | 0.91x | 1.01x | 0.87x | 0.15x | 0.84x | 0.94x | 0.86x | 0.97x |
| Revenue Growth | - | - | -100% | - | - | - | - | - | - | - |
ATXS SEC Filings & Documents
Astria Therapeutics, Inc. (ATXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ATXS Frequently Asked Questions
Astria Therapeutics, Inc. (ATXS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Astria Therapeutics, Inc. (ATXS) reported $0.7M in revenue for fiscal year 2024.
Astria Therapeutics, Inc. (ATXS) grew revenue by 0.0% over the past year. Growth has been modest.
Astria Therapeutics, Inc. (ATXS) reported a net loss of $124.0M for fiscal year 2024.
Dividend & Returns
Astria Therapeutics, Inc. (ATXS) has a return on equity (ROE) of -33.5%. Negative ROE indicates the company is unprofitable.
Astria Therapeutics, Inc. (ATXS) had negative free cash flow of $120.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More ATXS
Astria Therapeutics, Inc. (ATXS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates